EC extends license for Zytiga to treat early stage prostate cancer
The EC has granted approval to broaden the existing marketing authorisation for Zytiga to include early stage metastatic prostate cancer...
List view / Grid view
The EC has granted approval to broaden the existing marketing authorisation for Zytiga to include early stage metastatic prostate cancer...
A cheap and widely used drug, used to treat conditions such as heartburn, gastritis and ulcers, could work against the bacteria that cause TB...
Drugs designed to halt cancer growth may offer a new way to control high blood pressure...
Hemlibra has been approved to prevent the frequency of bleeding episodes in patients who have developed FVIII inhibitors...
A Norwegian study shows that NTZ contains a substance that can kill prostate and colon cancer...
NICE recommends Kisqali as a cost-effective treatment option for postmenopausal women within England and Wales with advanced breast cancer...
Studies show cell-based treatment is safe in patients with dry macular degeneration, with one showing improved vision...
The EU has approved a new subcutaneous formulation of Benlysta, as an add-on therapy in adult patients with active autoantibody-positive systemic lupus erythematosus...
The vaccine that protects against cancer-causing types of human papillomavirus also prevents an uncommon but incurable childhood respiratory disease...
Genes linked to schizophrenia in psychiatric patients suffering from bipolar disorder are the reason why such patients don't respond to the drug lithium...
The effect of combining clinically used drugs for the treatment of colon cancer analysed using novel open source software...
The FDA has approved a New Drug Application for Vyzulta for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension....
A vaccine combining centralised ancestral genes from four major influenza strains appears to provide broad protection against influenza...
Patients with advanced breast cancer who are treated with a combination of drugs are at increased risk of suffering adverse side effects...
The EMA recently introduced labelling requirements for some common excipients based on an in-depth assessment of their safety profiles, particularly in the paediatric population.1 This article considers their use in multidose products...